Overexpression of FGF2 modulates hormone receptor expression and induces endocrine resistance and breast cancer progression

FIGUEROA VIRGINIA; SAHORES ANA; VANZULLI SILVIA; MAY MARÍA; ABBA MARTIN; JACOBSEN BRITTA; LANARI CLAUDIA; LAMB CAROLINE

CABA

Congreso; Reunión Conjunta de Sociedades de Biociencias.; 2017

SAIC, SAIB, SAB, etc

Endocrine therapy is the standard treatment for patients with luminal breast cancer. However, resistance may develop as a result of enhanced growth factor signaling and the disease may progress to more complex stages. Fibroblast growth factor 2 (FGF2) consists of a secreted low molecular weight form (LMW-FGF2) and several nuclear high molecular weight forms (HMW-FGF2). We previously demonstrated that endocrine resistant mammary carcinomas display levels of progesterone receptor (PR) isoform A (PRA) lower than those of isoform B (PRB) and high levels of HMW-FGF2 compared to responsive tumors.